The venture capital group's partner institutions have successfully passed the review for the offshore protein technology innovation board.

On April 29, 2022, Nanjing Innovation Investment Group's partner organization, Jinyumaowu Investment Management Co., Ltd. (hereinafter referred to as "Jinyumaowu"), successfully passed the review of the Science and Technology Innovation Board Listing Committee for its invested company, Suzhou Nearshore Protein Technology Co., Ltd. (hereinafter referred to as "Nearshore Protein").

In 2021, Nanjing Innovation Investment Group reached a cooperation agreement with Jinyumaowu to strengthen the pharmaceutical and life health industry cluster in Nanjing, forming a new pattern of coordinated industrial chain development. Jinyumaowu is an excellent local investment institution in Nanjing, rooted in the city for many years, dedicated to discovering high-quality enterprises in Nanjing and introducing a large number of high-quality external enterprises, making outstanding contributions to the industrial transformation and development of Nanjing.

Nearshore Protein is a high-tech enterprise focused on recombinant protein application solutions, with its main business involving the research, development, production, and sales of target and cytokine proteins, recombinant antibodies, enzymes, and reagents. The company serves as an upstream supplier of raw materials and technical solutions in the medical health and life sciences fields, committed to providing downstream customers with timely, stable, and high-quality products and services, assisting global biopharmaceutical companies and research institutions in technological and product innovation upgrades.

Nearshore Protein breaks through traditional protein design concepts, directing the evolution of protein performance, and develops and produces high-performance antibodies and enzymes/reagents that meet pharmaceutical production requirements based on customer needs. The company has been deeply engaged in the recombinant protein industry for over a decade, providing high-quality products and services to thousands of enterprises and research institutions worldwide. With a good reputation established in the industry, Nearshore Protein has established cooperative relationships with well-known domestic and foreign companies such as AstraZeneca, Roche, Heng Rui Medicine, Watson Bio, Aibo Bio, Abbott, Wantai Bio, and Mingde Bio, assisting global biopharmaceutical companies in research and production.